Compare Figs Inc (FIGS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs GeneDx Holdings Corp — how do they compare? Figs Inc trades at $15.6 (market cap $2.49B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Figs Inc is the larger of the two by market cap, and Figs Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and GeneDx Holdings Corp for 19 Days on average.
| FIGS | WGS | |
|---|---|---|
Market Cap | $2.49B | $2.02B |
Volume | 5,964,311 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $167.51 |
52-Week Low | $6.90 | $34.51 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $2.25B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% over the past day, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while recent earnings beats and raised 2026 guidance highlight fundamental strength. Revenue growth accelerated to 28.8% in Q2 2026, with international sales surging 67%, and the company maintains a high gross margin of 68.91%.
The investment outlook is positive, with a consensus price target of $18.00 implying 14% upside. However, risks include a rich valuation (P/E of 45.39) and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, with 60% recommending buy, but investors should monitor margin pressures and competitive dynamics.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
